|
🐜
|
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
27 auth.
V. Heinemann,
L. V. von Weikersthal,
T. Decker,
A. Kiani,
U. Vehling‐Kaiser,
S. Al-Batran,
T. Heintges,
C. Lerchenmüller,
C. Kahl,
G. Seipelt,
F. Kullmann,
M. Stauch,
W. Scheithauer,
Jörg Hielscher,
M. Scholz,
...
S. Müller,
H. Link,
N. Niederle,
A. Rost,
H. Höffkes,
M. Moehler,
R. U. Lindig,
D. Modest,
Lisa Rossius,
T. Kirchner,
A. Jung,
S. Stintzing
|
10 |
2014 |
10
🐜
|
|
🦁
|
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
57 auth.
S. Al-Batran,
N. Homann,
C. Pauligk,
T. Goetze,
J. Meiler,
S. Kasper,
H. Kopp,
F. Mayer,
G. Haag,
K. Luley,
U. Lindig,
W. Schmiegel,
M. Pohl,
J. Stoehlmacher,
G. Folprecht,
...
S. Probst,
N. Prasnikar,
W. Fischbach,
R. Mahlberg,
J. Trojan,
M. Koenigsmann,
U. Martens,
P. Thuss-Patience,
M. Egger,
A. Block,
V. Heinemann,
G. Illerhaus,
M. Moehler,
M. Schenk,
F. Kullmann,
D. Behringer,
M. Heike,
D. Pink,
C. Teschendorf,
Carmen Löhr,
H. Bernhard,
G. Schuch,
V. Rethwisch,
L. F. V. Weikersthal,
J. Hartmann,
M. Kneba,
S. Daum,
K. Schulmann,
J. Weniger,
S. Belle,
T. Gaiser,
F. Oduncu,
M. Güntner,
W. Hozaeel,
Alexander Reichart,
E. Jäger,
T. Kraus,
S. Mönig,
W. Bechstein,
M. Schuler,
H. Schmalenberg,
R. Hofheinz
|
10 |
2019 |
10
🦁
|
|
🦁
|
Chemotherapy for advanced gastric cancer.
S. Al-Batran,
E. Jäger,
M. Scholz
|
10 |
2007 |
10
🦁
|
|
🐜
|
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
153 auth.
K. Shitara,
M. Özgüroğlu,
Y. Bang,
M. Di Bartolomeo,
M. Mandalà,
M. Ryu,
L. Fornaro,
T. Olesiński,
C. Caglevic,
H. Chung,
K. Muro,
E. Goekkurt,
W. Mansoor,
R. McDermott,
E. Shacham-Shmueli,
...
Xinqun Chen,
C. Mayo,
S. Kang,
A. Ohtsu,
C. Fuchs,
G. Lerzo,
J. O'Connor,
G. Mendez,
J. Lynam,
N. Tebbutt,
M. Wong,
A. Strickland,
C. Karapetis,
D. Goldstein,
P. Vasey,
J. Van Laethem,
E. Van Cutsem,
S. Berry,
M. Vincent,
Bettina Muller,
F. Rey,
A. Zambrano,
J. Guerra,
M. Krogh,
L. Baeksgaard,
M. Yilmaz,
A. Elme,
Andrus Magi,
P. Auvinen,
T. Alanko,
M. Moehler,
V. Kunzmann,
T. Seufferlein,
P. Thuss-Patience,
T. Hoehler,
G. Haag,
S. Al-Batran,
H. Castro,
K. Lopez,
Mynor Aguilar Vasquez,
Mario Sandoval,
K. Lam,
S. Cuffe,
C. Kelly,
R. Geva,
A. Hubert,
A. Beny,
B. Brenner,
Aprile Giuseppe,
A. Falcone,
E. Maiello,
R. Passalacqua,
V. Montesarchio,
H. Hara,
K. Chin,
T. Nishina,
Y. Komatsu,
N. Machida,
S. Hironaka,
T. Satoh,
T. Tamura,
Naotaoshi Sugimoto,
Haruhiko Cho,
Yashushi Omuro,
Ken Kato,
M. Goto,
I. Hyodo,
Kazuhiro Yoshida,
H. Baba,
T. Esaki,
J. Furuse,
Wan Zamaniah Wan Mohammed,
Carlos Hernandez Hernandez,
Juan Casas Garcia,
Adriana Dominguez Andrade,
Katriona Clarke,
G. Hjortland,
N. Glenjen,
T. Kubiatowski,
J. Jacek,
M. Wojtukiewicz,
S. Lazarev,
Yuri Lancukhay,
Sergey Afanasayev,
V. Moiseyenko,
V. Kostorov,
S. Protsenko,
V. Shirinkin,
D. Sakaeva,
N. Fadeeva,
W. Yong,
C. Ng,
B. Robertson,
B. Rapaport,
G. Cohen,
L. Dreosti,
P. Ruff,
C. Jacobs,
G. Landers,
W. Szpak,
S. Roh,
Jeeyun Lee,
Yeul-Hong Kim,
H. Chung,
Maria Alsina Maqueda,
F. Longo Muñoz,
Andres Cervantes Aguilar,
Enrique Aranda Aguilar,
P. García Alfonso,
F. Rivera,
Jaime Feliu Batle,
R. Pazo Cid,
K. Yeh,
Jen‐Shi Chen,
Y. Chao,
C. Yen,
O. Kara,
Ş. Yalçın,
D. Hochhauser,
I. Chau,
A. Benson,
V. Shankaran,
W. Shaib,
P. Philip,
V. Sharma,
R. Siegel,
Weijing Sun,
Z. Wainberg,
B. George,
A. Bullock,
S. Myrick,
Josephine Faruol,
Richard Siegel,
T. Larson,
C. Becerra,
Suresh Ratnam,
D. Richards,
Stephen L. Riche
|
9 |
2018 |
9
🐜
|
|
🐜
|
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
23 auth.
H. Joensuu,
M. Eriksson,
K. Sundby Hall,
J. Hartmann,
D. Pink,
J. Schütte,
G. Ramadori,
P. Hohenberger,
J. Duyster,
S. Al-Batran,
...
M. Schlemmer,
S. Bauer,
E. Wardelmann,
M. Sarlomo‐Rikala,
B. Nilsson,
H. Sihto,
O. Monge,
P. Bono,
R. Kallio,
Aki Vehtari,
M. Leinonen,
T. Alvegård,
P. Reichardt
|
9 |
2012 |
9
🐜
|
|
🦁
|
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
20 auth.
S. Al-Batran,
J. Hartmann,
S. Probst,
H. Schmalenberg,
S. Hollerbach,
R. Hofheinz,
V. Rethwisch,
G. Seipelt,
N. Homann,
G. Wilhelm,
...
G. Schuch,
J. Stoehlmacher,
H. Derigs,
S. Hegewisch‐Becker,
J. Grossmann,
C. Pauligk,
A. Atmaca,
C. Bokemeyer,
A. Knuth,
E. Jäger
|
9 |
2008 |
9
🦁
|
|
🐜
|
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
22 auth.
D. Le,
Tae Won Kim,
E. Van Cutsem,
R. Geva,
D. Jäger,
H. Hara,
M. burge,
B. O'Neil,
P. Kavan,
T. Yoshino,
...
R. Guimbaud,
H. Taniguchi,
E. Élez,
S. Al-Batran,
P. Boland,
T. Crocenzi,
C. Atreya,
Yi Cui,
T. Dai,
P. Marinello,
Luis A. Diaz Jr,
T. André
|
9 |
2019 |
9
🐜
|
|
🦁
|
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multice
40 auth.
S. Al-Batran,
R. Hofheinz,
C. Pauligk,
H. Kopp,
G. Haag,
K. Luley,
J. Meiler,
N. Homann,
S. Lorenzen,
H. Schmalenberg,
S. Probst,
M. Koenigsmann,
M. Egger,
N. Prasnikar,
K. Caca,
...
J. Trojan,
U. Martens,
A. Block,
W. Fischbach,
R. Mahlberg,
M. Clemens,
G. Illerhaus,
K. Zirlik,
D. Behringer,
W. Schmiegel,
M. Pohl,
M. Heike,
U. Ronellenfitsch,
M. Schuler,
W. Bechstein,
A. Königsrainer,
T. Gaiser,
P. Schirmacher,
W. Hozaeel,
Alexander Reichart,
T. Goetze,
M. Sievert,
E. Jäger,
S. Mönig,
A. Tannapfel
|
9 |
2016 |
9
🦁
|
|
🐜
|
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
15 auth.
M. Rummel,
S. Al-Batran,
Soo‐Zin Kim,
M. Welslau,
Ralf Hecker,
D. Kofahl-Krause,
K. Josten,
H. Dürk,
A. Rost,
M. Neise,
...
U. von Gruenhagen,
K. Chow,
M. Hansmann,
D. Hoelzer,
P. Mitrou
|
8 |
2005 |
8
🐜
|
|
🐜
|
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
20 auth.
A. Ohtsu,
J. Ajani,
Y. Bai,
Y. Bang,
H. Chung,
H. Pan,
T. Sahmoud,
L. Shen,
K. Yeh,
K. Chin,
...
K. Muro,
Yeul-Hong Kim,
D. Ferry,
N. Tebbutt,
S. Al-Batran,
Heind Smith,
C. Costantini,
S. Rizvi,
D. Lebwohl,
E. Van Cutsem
|
8 |
2013 |
8
🐜
|
|
🐜
|
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
23 auth.
S. Stintzing,
D. Modest,
Lisa Rossius,
M. Lerch,
L. V. von Weikersthal,
T. Decker,
A. Kiani,
U. Vehling‐Kaiser,
S. Al-Batran,
T. Heintges,
...
C. Lerchenmüller,
C. Kahl,
G. Seipelt,
F. Kullmann,
M. Stauch,
W. Scheithauer,
S. Held,
C. Gießen-Jung,
M. Moehler,
A. Jagenburg,
T. Kirchner,
A. Jung,
V. Heinemann
|
8 |
2016 |
8
🐜
|
|
🦁
|
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial
28 auth.
S. Al-Batran,
N. Homann,
C. Pauligk,
G. Illerhaus,
U. Martens,
J. Stoehlmacher,
H. Schmalenberg,
K. Luley,
N. Prasnikar,
M. Egger,
S. Probst,
H. Messmann,
M. Moehler,
W. Fischbach,
J. Hartmann,
...
F. Mayer,
H. Höffkes,
M. Koenigsmann,
D. Arnold,
T. Kraus,
Kersten Grimm,
Stefan Berkhoff,
S. Post,
E. Jäger,
W. Bechstein,
U. Ronellenfitsch,
S. Mönig,
R. Hofheinz
|
8 |
2017 |
8
🦁
|
|
🐢
|
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.
12 auth.
Y. Janjigian,
D. Werner,
C. Pauligk,
K. Steinmetz,
D. Kelsen,
E. Jäger,
...
H. Altmannsberger,
E. Robinson,
L. Tafe,
Laura H. Tang,
Manish A. Shah,
S. Al-Batran
|
8 |
2012 |
8
🐢
|
